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Abstract
Background: A randomized trial of vinorelbine plus gemcitabine followed by docetaxel (VGD) versus paclitaxel
plus carboplatin (PC) in patients with advanced non-small-cell lung cancer showed no difference in overall survival
(median survival time: 13.6 versus 14.1 months) between the two treatment groups. We report here the results of
quality-of-life (QOL) study initiated in the mid-course of this randomized trial.
Methods: The patients themselves assessed the Functional Assessment of Cancer Therapy (FACT)-Lung (FACT-L),
FACT-Taxane and the Functional Assessment of Chronic Illness Therapy - Spirituality (FACIT-Sp) QOL instruments at
baseline and 6, 12 and 18 weeks after the treatment. The primary endpoint was a comparison of total QOL score
for each assessment instrument between the two groups.
Results: Sixty-eight patients from the trial (VGD, 34; PC, 34) who submitted baseline questionnaires and at least
one questionnaire over the course of treatment were eligible. Longitudinal analysis showed a significant difference
in slope of the FACT-Taxane score (p = 0.004) between treatment regimens over time, but no difference was
found in FACT-L score (p = 0.311) and FACIT-Sp score (p = 0.466) between the two groups.
Conclusions: The significant difference in slope of FACT-Taxane score favored the VGD regimen. These data should
be considered in treatment decision-making for patients with advanced non-small-cell lung cancer.
Trial registration: NCT00242983.
Background
Non-small-cell lung cancer (NSCLC) accounts for
approximately 75-85% of all cases of lung cancer [1-3].
More than 70% of patients have locally advanced or
incurable metastatic disease [4]. Overall 5-year survival
is approximately 14%. The goal of treatment for patients
with recurrent or metastatic NSCLC remains palliative.
Experience over the past three decades has shown
improvements in survival, symptom control and quality
of life (QOL) in patients with metastatic NSCLC who
receive first-line chemotherapy [5-7]. The benefits of
treatment must outweigh the risks, and patient-focused
outcomes and optimization of well-being are of para-
mount importance for individuals who have limited life
expectancy [8,9]. Thus, we designed a QOL study (BRI
LC03-01) to be run during an ongoing randomized con-
trolled trial (Japan Multinational Trial Organization
(JMTO) LC00-03[10]). Data were obtained using the
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(FACT-L), FACT-Taxane and the Functional Assess-
ment of Chronic Illness Therapy - Spirituality (FACIT-
Sp) QOL assessment instruments.
Methods
Study population
This study (BRI LC03-01) was conducted as one of the
additional studies of JMTO LC00-03 trial. As an explora-
tory trial, this study was started in the mid-course of the
JMTO LC00-03 trial period (Figure 1). The comprehen-
sive details on the whole patient population studied and
methods employed was shown in the JMTO LC00-03
report [10]. Briefly, between March 2001 and April 2005
from 45 institutions in Japan, 401 chemotherapy-naïve
NSCLC patients with stage IIIB disease with pleural effu-
sion or stage IV disease without brain metastasis were
randomized to one of two treatment regimens. These
were either the vinorelbine plus gemcitabine followed
by docetaxel (VGD) group (intravenous vinorelbine
25 mg/m
2 plus gemcitabine 1000 mg/m
2 on days 1 and 8
every 21 days for three cycles, followed by intravenous
docetaxel 60 mg/m
2, on day 1 every 21 days for three
cycles) or the paclitaxel plus carboplatin (PC) group
(intravenous paclitaxel 225 mg/m
2 plus carboplatin
AUC = 6 for 3 h on day 1 every 21 days for six cycles).
The eligibility criteria for this study (BRI LC03-01) were
t h es a m ea sf o rt h eJ M T OL C 0 0 - 0 3t r i a la n di n c l u d e d
written informed consent to enter this QOL study. The
criteria of the JMTO LC00-03 trial included cytologically
or histologically confirmed NSCLC, stage IIIB (plueral
effusion) or IV, chemotherapy-naïve, age 18 years and
over, ECOG performance status 0 or 1, adequate organ
function and no brain metastasis. The study protocol was
approved by the ethics committee at each institution.
QOL assessment
QOL was assessed using FACT-L [11], FACT-Taxane
[12], and FACIT-Sp [13,14] at baseline (pre-treatment),
prior to the third treatment cycle (Week 6), prior to the
401 enrolled patients (JMTO LC00-03)
109 screened patients (BRI LC03-01)
201 patients randomly assigned to VGD group 
(JMTO LC00-03)
53 patients (BRI LC03-01)
200 patients randomly assigned to PC group
(JMTO LC00-03)
14 patients excluded due to not 
informed consent
14 patients excluded for study
1 with other malignancy
2 with withdrawal of consent
11 with not informed consent
39 enrolled patients 42 enrolled patients 
34 patients included in analysis
5 patients excluded from analysis
1 patient had no baseline QOL data
1 patient had only undergone 
the first cycle of chemotherapy
3 patients had no follow- up data
8 patients excluded from analysis
1 patient had no baseline QOL data
1 patient had no follow- up data
2 patients had only undergone 
the first cycle of chemotherapy 
4 patients not calculated QOL score
56 patients (BRI LC03-01)
34 patients included in analysis
Figure 1 Trial profile.
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Page 2 of 8fifth treatment cycle (Week 12), and at the end of sixth
treatment cycle (Week 18) or at study withdrawal. In
this study, these were self-administered by patients.
FACT-L
The FACT-L instrument is a multidimensional question-
naire developed and validated for use in lung cancer
patients; it includes the 27-item FACT-General (FACT-G;
version 4 in Japanese) questionnaire targeted to general
cancer patients and seven questions specific to issues
faced by lung cancer patients (lung cancer subscale, LCS).
The FACT-G version 4 questionnaire includes the follow-
ing four subscales: physical well-being (PWB; seven items),
social/family well-being (seven items), emotional well-
being (six items) and functional well-being (FWB; seven
items). These subscales can be analyzed separately or
aggregated to produce a total QOL score. FACT-G has
demonstrated reliability, validity and responsiveness to
change over time [15].
FACT-Taxane
FACT-Taxane comprises the FACT-G questionnaire
plus a 16-item Taxane subscale (version 4 in Japanese).
T h eT a x a n es u b s c a l ec o m b i n e st h ev a l i d a t e d1 1 - i t e m
neurotoxity subscale and five additional questions asses-
sing symptoms related to arthralgia, myalgia and skin
discoloration. The FACT-Taxane instrument is validated
for use in lung cancer patients [12].
FACIT-Sp
FACIT-Sp comprises the FACT-G questionnaire plus a
12-item spirituality subscale (version 4 in Japanese). The
FACIT-Sp subscale comprises two factors. One of these
(labeled meaning/peace) includes eight items and assesses
the sense of meaning, peace and purpose in life. The other
(labeled faith) contains four items and measures several
aspects of the relationship between illness and one’s faith
and spiritual beliefs. The Japanese version of the FACIT-
Sp scale is satisfactory in terms of reliability and validity
and is a useful tool in the study of spirituality among Japa-
nese cancer patients including lung cancer [14].
FACT-G, lung cancer subscale, Taxane subscale and
spirituality subscale were each scored using a five-point
scale (0 = not at all; 1 = a little bit, 2 = somewhat; 3 =
quite a bit; 4 = very much). According to Functional
Assessment of Chronic Illness Therapy (FACIT) scoring
guidelines [15], these scores were calculated only when
patients responded to at least 80% of the items that consti-
tuted the relevant score. The ranges of possible total
scores are 0-136 in FACT-L, 0-172 in FACT-Taxane and
0-156 in FACIT-Sp. The FACT-G score is calculated by
summing four of the five unweighted subscale scores, spe-
cially the PWB, SWB, EWB, and FWB scores (i.e., exclud-
ing the LCS), with score in the range of 0-108. The trial
outcome index (TOI), an efficient summary index of phy-
sical/functional outcomes, is the sum of the PWB, FWB,
and specific subscale (LCS or Taxane subscale) scores.
The ranges of TOI scores are 0-84 in FACT-L and 0-120
in FACT-Taxane. For all items and domains, higher scores
are associated with better QOL.
Statistical considerations
The primary objective of this study was to test whether the
VGD regimen produced better QOL compared with the
PC regimen in patients with advanced NSCLC. The pri-
mary endpoints were total scale scores of FACT-L, FACT-
Taxane, and FACIT-Sp. Secondary endpoints were sub-
scale scores of FACT-L, FACT-Taxane, and FACIT-Sp.
We initially planned that we could enrol 200 patients on
the basis of the feasibility.
The mean scores for the specific scales were calculated
within groups based on treatment at each period of the
assessment. A change in QOL outcome was calculated by
subtracting an individual’s scores during treatment from
that patient’s baseline score. Patients who dropped out
a n do n l ys u b m i t t e daQ O La s s e s s m e n ta tt h eb a s e l i n e
were excluded from this study. We assumed that missing
a QOL assessment was a random event (missing at ran-
dom, MAR): that discontinuation of the QOL assessment
depended on previous QOL assessments, but was inde-
pendent of future ones. QOL assessments in a group-
based analysis were performed by analyzing changes of the
mean scores over the course of treatment with a general
linear mixed-effects model. The mixed-effects modeling
included the main effect of treatment group (difference in
overall mean between groups) and an interaction effect of
treatment group and time (difference in slope between
groups) under the MAR assumption. Statistical analyses
were performed by using SAS version 9.1 (SAS Institute,
Cary, NC, USA).
Results
Out of 401 enrolled patients in JMTO LC00-03, 109
patients were screened for BRI LC03-01 between January
2004, and April 2005, from 14 institutions in Japan
(Figure 1). Twenty-five patients (VGD group, 14; PC
group, 11) who did not provide the consent for the QOL
study, and three in PC group were ineligible for the
JMTO LC00-03 trial (1 had other malignancy and 2 with-
drew informed consent). Although total eighty-one
patients were enrolled in this study, thirteen patients
(VGD group, 5; PC group, 8) were excluded from the
analysis: two patients had no baseline QOL data (VGD
group, 1; PC group, 1), four patients had no QOL follow-
up data (VGD group, 3; PC group, 1), three patients had
only undergone the first course of chemotherapy (VGD
group, 1; PC group, 2), and four patients fulfilled QOL in
less than 80% of any one questionnaire (FACT L, FACT-
Taxane, and FACIT-Sp) at baseline (two patients) and
after the second course of chemotherapy (two patients)
in PC group. Sixty-eight patients from the trial (VGD
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questionnaire and at least one questionnaire over the
course of the treatment, were included in the analysis.
Table 1 shows the patient characteristics of each group.
Significantly more female patients were distributed to the
PC group (44%) than to the VGD group (18%) (p = 0.003).
Other factors such as age, ECOG performance status, his-
tology, stage, weight loss and serum lactate dehydrogenase
(LDH) were well balanced between the PC and VGD
groups. More than half of the patients had adenocarci-
noma and/or stage IV disease.
Compliance with QOL assessment in each group is
shown in Table 2. In both groups, the compliance - rate of
submitted questionnaires - was very high; 97% at 6 weeks,
96% at 12 weeks and 92% at 18 week in the PC group and
97, 96 and 90% in the VGD group, respectively. Mean
QOL score and subscales in each group are summarized
in Table 3. Baseline score showed no significant differ-
ences from the overall mean score between groups in the
FACT-L (p = 0.272) (Figure 2), FACT-Taxane (p = 0.188)
(Figure 3) or FACIT-Sp (p = 0.062) (Figure 4) score.
Although there were no significant differences in slope
between groups for FACT-L (p = 0.311) (Figure 2) or
FACIT-Sp (p = 0.466) (Figure 4), there was a significant
difference in slope of the FACT-Taxane score (p = 0.004)
(Figure 3). When FACT-Taxane score was assessed over
time, the score became significantly worse in the PC
group than in the VGD group. We performed post-hoc
subgroup analysis according to sex to evaluate the FACT-
Taxane score because the VGD group included fewer
female patients. The mean changes from baseline score at
18 weeks in the FACT-Taxane instrument for male and
female patients were -49.7 (N = 7) and -33.4 (N = 5) in
the PC group, and -7.4 (N = 15) and 1.0 (N = 3) in the
VGD group respectively. This indicates that there was no
difference for change in FACT-Taxane score according to
sex between treatment groups.
Discussion
Treatment of advanced metastatic NSCLC is palliative
rather than curative and therefore should focus on relief of
symptoms as well as extension of survival time. Further-
more, the benefits of chemotherapy should outweigh fac-
tors such as toxicity and inconvenience to the patient.
Thus, an adequate assessment of the impact of treatment
on patient health in the setting of metastatic disease
requires measurement of the effects of the therapy on can-
cer-specific symptoms, treatment-related toxicity and
domains of patient health. Assessment of the impact of
treatment on QOL provides a comprehensive understand-
ing of the overall burden or benefit of therapy to patients.
The present BRI LC03-01 QOL evaluation study demon-
strates that patients treated with the VGD regimen gener-
ally experienced an improvement in their QOL compared
Table 1 Baseline patients characteristics
Characteristics PC group (n = 34) VGD group (n = 34)
Age, years
Median 66 64
Range (33-75) (39-79)
Sex, n (%)
Male 19 (56%) 28 (82%)
Female 15 (44%) 6 (18%)
ECOG performance status, n (%)
0 12 (35%) 15 (44%)
1 22 (65%) 19 (56%)
Histologic type, n (%)
Adenocarcinoma 26 (76%) 22 (65%)
Squamous cell 5 (15%) 9 (26%)
Other 3 (9%) 3 (9%)
Stage, n (%)
IIIB 3 (9%) 4 (12%)
IV 31 (91%) 30 (88%)
Weight loss (from 6 months before enrolment, n (%)
<5% 29 (85%) 31 (91%)
≥5% 5 (15%) 3 (9%)
LDH concentration, n (%)
Normal 28 (82%) 28 (82%)
Abnormal 6 (18%) 6 (18%)
LDH, lactate dehydrogenase.
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cant difference was found in slope of the FACT-Taxane
score (p = 0.004). Patients in the VGD group showed no
significant mean variation over time in their QOL score,
while the patients on the PC group showed a steady
decline in FACT-G and FACT-Taxane score over time
(Table 3). In terms of general health, patients receiving the
VGD regimen had better QOL than those receiving PC
treatment, as assessed by the FACT-L, FACT-Taxane and
FACIT-Sp scores. JMTO LC00-03, a randomized trial of
the VGD and PC regimens in patients with advanced
NSCLC, showed differences between the two treatment
groups in terms of response rate (25 versus 37%) and regi-
men-specific toxicity, including taxane-related toxicities
such as arthralgia (0 versus 8.6%), myalgia (0 versus 7.1%)
and neuropathy (0.5 versus 9.6%). However, there were no
differences in overall survival (median survival time, 13.6
versus 14.1 months) [10]. This study of the VGD and PC
regimens in patients with advanced NSCLC differences
between the two treatment groups in terms of taxane-
related toxicities such as grade 3 or 4 arthralgia (0 versus
18%), motor neuropathy (3 versus 12%) and sensory neu-
ropathy (3 versus 18%). The QOL scores of patients with
non-small cell lung cancer usually decrease during che-
motherapy [16]. However, the QOL score is maintained
despite treatment advances in the VGD group. The
adverse effect of VGD seems to be less than that of PC.
We can be reasonably confident that the statistically signif-
icant improvement seen in the QOL of patients treated
with either VGD or PC was clinically meaningful, as the
results from the QOL assessment tools, in addition to
other parameters, such as change in performance status
and weight, were very consistent.
The study has some limitations. Firstly, sample size
could not be determined based on statistical consideration.
Secondly, the numbers of patients actually accrued were
fewer than expected, because it took substantial time to
get approvement and initiate this trial in each institution
in mid-course of the parent phase III trial. Poor compli-
ance with QOL assessments is one of the major methodo-
logical problems seen in studies of QOL, as patients
experiencing deteriorations in QOL are less likely to com-
ply with future QOL assessments, potentially producing
biased results [17]. Although small number, all the
patients (PC group: 12, VGD group: 16) who completed
the study treatment made the QOL questionnaire
Table 2 Compliance with QOL assessment
PC group (n = 34) VGD group (n = 34)
Assessment time Baseline 6 week 12 week 18 week Baseline 6 week 12 week 18 week
No. of evaluable patients 34 34 23 13 34 34 24 20
Discontinuation of protocol treatment 0 0 11 10 0 0 10 4
Investigator’s error 0 1 1 1 0 1 0 1
No reason provided 0 0 0 0 0 0 1 1
No. of submitted questionnaires
Compliance (%)
34
100%
33
97%
22
96%
12
92%
34
100%
33
97%
23
96%
18
90%
Table 3 Means QOL scores over time
PC group (n = 34), mean (SD) VGD group (n = 34), mean (SD)
Assessment time Baseline 6 week 12 week 18 week Baseline 6 week 12 week 18 week
FACT-G
Physical well-being (7 items) 21.8 (5.3) 16.9 (7.1) 16.1 (5.4) 12.8 (5.7) 21.4 (5.3) 19.1 (6.7) 20.2 (6.2) 20.2 (5.1)
Social/family well-being (7 items) 19.7 (4.7) 19.7 (5.0) 18.9 (6.2) 19.4 (5.2) 18.9 (6.0) 19.6 (4.9) 20.1 (5.1) 17.2 (6.0)
Emotional well-being (6 items) 16.1 (5.1) 15.6 (5.9) 15.5 (6.4) 13.6 (5.6) 14.1 (5.8) 16.3 (5.5) 16.8 (5.1) 16.4 (5.5)
Functional well-being (7 items) 17.5 (6.7) 14.9 (6.3) 15.2 (6.6) 13.1 (5.4) 16.2 (6.9) 17.2 (6.5) 19.2 (6.0) 16.4 (7.2)
FACT-G total (27 items) 73.0 (15.4) 65.1 (17.5) 63.4 (17.4) 57.1 (14.7) 69.0 (12.8) 70.3 (16.7) 74.6 (15.7) 68.9 (16.5)
FACT-L
Lung cancer subscale (7 items) 19.0 (5.1) 19.3 (3.8) 19.3 (4.8) 18.8 (4.2) 18.9 (3.7) 18.9 (6.0) 20.3 (4.5) 20.4 (5.1)
Trial outcome index-lung (21 items) 57.6 (12.5) 51.2 (13.3) 49.9 (13.8) 44.6 (10.6) 56.2 (10.8) 55.1 (15.9) 59.7 (14.2) 57.0 (14.8)
FACT-Taxane
Neurotoxicity (11 items) 40.3 (4.1) 30.0 (9.4) 24.3 (9.3) 16.0 (7.2) 39.6 (5.6) 37.4 (7.2) 38.9 (5.5) 37.0 (7.0)
Taxane (16 items) 59.9 (4.3) 47.5 (12.0) 41.0 (11.7) 30.4 (9.9) 59.1 (6.8) 56.5 (8.9) 58.3 (6.1) 55.4 (9.3)
Trial outcome index-taxane (30 items) 98.9 (13.7) 78.9 (21.2) 70.9 (17.4) 55.8 (15.9) 96.7 (11.9) 92.5 (18.0) 97.7 (15.1) 91.8 (16.8)
FACIT-Sp
Spirituality (12 items) 30.3 (9.8) 30.1 (9.6) 28.3 (11.8) 27.2 (12.4) 28.4 (11.5) 29.6 (9.8) 28.3 (11.4) 30.0 (9.4)
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Page 6 of 8completed. This was a well designed and executed rando-
mized clinical trial, but the QOL portion of the trial had
these limitation.
Conclusions
A significant difference in slope of FACT-Taxane was
found in favour of non-platinum VGD regimen. Tax-
ane-related toxicities such as arthralgia, myalgia and
neuropathy are statistically more frequent in the PC
regimen than in the VGD one. Significant differences in
other global and specific health-related QOL could not
be demonstrated probably due to the limited number of
patients. Although this study could be considered a pre-
liminary study, given its limited small sample size, these
data, especially FACT-Taxane, should be considered in
treatment decision-making for patients with advanced
non-small-cell lung cancer.
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